A61K 40/4203
Receptors for growth factors
Official title: {Receptors for growth factors}
A61K40/4203 (Receptors for growth factors) appears on 413 US grants and 1,113 published applications in this corpus.
Search patents in A61K- Granted patents
- 413
- Published applications
- 1,113
- Assignees
- 451
- Inventors
- 1,925
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 7 |
| 2003 | 3 | 4 |
| 2004 | 0 | 5 |
| 2005 | 0 | 5 |
| 2006 | 2 | 5 |
| 2007 | 1 | 0 |
| 2008 | 2 | 9 |
| 2009 | 2 | 6 |
| 2010 | 7 | 8 |
| 2011 | 3 | 8 |
| 2012 | 6 | 7 |
| 2013 | 2 | 10 |
| 2014 | 5 | 13 |
| 2015 | 5 | 14 |
| 2016 | 12 | 20 |
| 2017 | 7 | 47 |
| 2018 | 11 | 47 |
| 2019 | 10 | 58 |
| 2020 | 22 | 95 |
| 2021 | 34 | 107 |
| 2022 | 59 | 145 |
| 2023 | 50 | 125 |
| 2024 | 56 | 154 |
| 2025 | 61 | 123 |
| 2026 | 48 | 91 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 40/4205Her-2/neu/erbb2, her-3/erbb3 or her 4/ erbb4289
- A61K 40/4204Epidermal growth factor receptors [egfr]153
- A61K 40/4208Vascular endothelial growth factor receptors [vegfr]15
- A61K 40/4209Hepatocyte growth factor receptor [hgfr] or c-met]4
- A61K 40/4206Fibroblast growth factor receptors [fgfr]3
- A61K 40/4207Platelet-derived growth factor receptors [pdgfr]2
Recent patents
- Methods of activating cells via PTP 1B inhibition29 Sep 2026US 12,746,285 B2Monash University
- Chimeric antigen receptor for treatment of cancer29 Sep 2026US 12,747,278 B2Industry-Academic Cooperation Foundation, Yonsei University
- Genetically engineered phagocytes, and related compositions, vectors, methods and systems22 Sep 2026US 12,741,025 B2The Regents of the University of California
- Chimeric antigen receptors to HER2 and methods of use thereof22 Sep 2026US 12,742,020 B2BioAtla, Inc.
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Chimeric Cytokine Receptors and Methods of Use8 Oct 2026US 2026/0308235 A1
- Small Molecule Based Method Of Modifying T Cells8 Oct 2026US 2026/0308520 A1Agency for Science, Technology and Research
- Car-t cells co-expressing cd40l1 Oct 2026US 2026/0294969 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Viral vectors for cell therapy1 Oct 2026US 2026/0294971 A1
- T-cell receptors targeting her2 and methods of use thereof1 Oct 2026US 2026/0297158 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Chimeric receptor genes and cells transformed therewith327US 7,741,465 B12010
- Chimeric receptor genes and cells transformed therewith196US 8,211,422 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2012
- Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated114US 5,801,005 AUniversity of Washington · 1998
- Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor113US 9,394,368 B2Novartis AG · 2016
- T cell modifying compounds and uses thereof108US 9,597,357 B2Sangamo BioSciences, Inc. · 2017